(Q37504684)

20 August 2017

1 reference

title

Targeted therapy for hepatocellular carcinoma. (English)

1 reference

20 August 2017

Hans Christian Spangenberg

series ordinal

1

1 reference

20 August 2017

Robert Thimme

series ordinal

2

1 reference

20 August 2017

Hubert E Blum

series ordinal

3

1 reference

20 August 2017

language of work or name

English

0 references

publication date

2 June 2009

1 reference

Nature Reviews Gastroenterology & Hepatology

20 August 2017

1 reference

20 August 2017

6

1 reference

20 August 2017

7

1 reference

20 August 2017

423-432

1 reference

https://scigraph.springernature.com/pub.10.1038/nrgastro.2009.86

20 August 2017

0 references

cites work

Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96).

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

AASLD single-topic research conference on hepatocellular carcinoma: Conference proceedings

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Management of hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Novel advancements in the management of hepatocellular carcinoma in 2008.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Primary liver cancer: worldwide incidence and trends

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

The influence of alcohol consumption and hepatitis B and C infections on the risk of liver cancer in Europe

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Hepatocellular carcinoma: recent trends in the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Environmental factors and risk for hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Alcohol and hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Obesity and hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Clinical features of hepatocellular carcinoma seronegative for both HBsAg and anti-HCV antibody but positive for anti-HBc antibody in Japan

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Joint effects of coffee consumption and serum gamma-glutamyltransferase on the risk of liver cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Coffee drinking and hepatocellular carcinoma risk: a meta-analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Coffee Consumption and Risk of Liver Cancer: A Meta-Analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Diagnosis and staging of hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Hepatocellular carcinoma: diagnosis and treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Prognosis of hepatocellular carcinoma: the BCLC staging classification

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Molecular pathogenesis of human hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Tumour suppressors in liver carcinogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Genomics and signaling pathways in hepatocellular carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Focus on hepatocellular carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Hepatocellular carcinoma pathogenesis: from genes to environment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Liver stem cells and hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Genetic aspects of hepatocellular carcinogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Liver pathology in obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Telomeres and telomerase: a dual role in hepatocarcinogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Immune pathogenesis of hepatocellular carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Prevention of hepatocellular carcinoma development associated with chronic hepatitis by anti-fas ligand antibody therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

NF-kappaB functions as a tumour promoter in inflammation-associated cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Interaction of hepatitis B virus, chemical carcinogen, and genetic susceptibility: multistage hepatocarcinogenesis with multifactorial etiology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Tyrosine kinases as targets for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Molecular targeted therapies in hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Liver transplantation in patients with hepatocellular carcinoma across Milan criteria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Low-dose thalidomide treatment for advanced hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Pamidronate induced anti-proliferative, apoptotic, and anti-migratory effects in hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Molecular therapy for the treatment of hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Molecularly targeted therapy for hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Sorafenib in advanced hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Sorafenib in liver cancer--just the beginning

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Sorafenib in advanced hepatocellular carcinoma - We have won a battle not the war.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Design and endpoints of clinical trials in hepatocellular carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Opportunities for targeted therapies in hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Hepatocellular carcinoma: molecular pathways and new therapeutic targets.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

New therapies for hepatocellular carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Molecular targeted therapies in hepatocellular carcinoma: From pre-clinical models to clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Targeting EGFR in colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Moving targets in hepatocellular carcinoma: hepatic progenitor cells as novel targets for tyrosine kinase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Phase II study of imatinib in unresectable hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Gene expression in fixed tissues and outcome in hepatocellular carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.86

An update on the molecular genetics of hepatocellular carcinoma.

31 March 2020

1 reference

12 December 2020

Alpha-1-thymosin and transcatheter arterial chemoembolization in hepatocellular carcinoma patients: a preliminary experience.

1 reference

12 December 2020

Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas

1 reference

12 December 2020

Thymostimulin treatment of hepatocellular carcinoma on liver cirrhosis

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRGASTRO.2009.86

1 reference

release_txrgmh4rovgf7kzj2etvmg5arm

20 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/txrgmh4rovgf7kzj2etvmg5arm

24 November 2022

mapped directly with Wikidata item

1 reference